But the drugs can also cause significant loss of muscle mass
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 18 Appendicitis After Initiation of Tirzepatide Authors Chan G , Ansar M, Klein M Received 9 October 2024 Accepted for publication 15 January 2025 Published 31 January 2025 Volume 2025:18 Pages 261265 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Dr Halis Akturk Garrett Chan 1 , Mariam Ansar 1 , Marlena Klein 1,2 1 Department of Internal Medicine, Cooper University Hospital, Camden, New Jersey, USA
These therapies continue to demonstrate meaningful reductions in A1C, body weight, and cardiovascular events
It is often a fit for people whose hunger has defeated repeated diet attempts, for those whose progress on semaglutide or tirzepatide has plateaued, and for those with insulin resistance or prediabetes who benefit from steadier post-meal blood sugar
Cost comparison: semaglutide vs